[1] |
MARUKI T, IWAMOTO N, KANDA K, et al. Two cases of breakthrough severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) infections caused by the Omicron variant(B.1.1.529 lineage)in international travelers to Japan[J]. Clin Infect Dis, 2022, 75(1):e354-e356. doi: 10.1093/cid/ciab1072.
|
[2] |
MOHAPATRA R K, SARANGI A K, KANDI V, et al. Omicron(B.1.1.529 variant of SARS-CoV-2);an emerging threat:Current global scenario[J]. J Med Virol, 2022, 94(5):1780-1783. doi: 10.1002/jmv.27561.
|
[3] |
CASTRO-CASTRO M J, GARCIA-TEJADA L, ARBIOL-ROCA A, et al. Dynamic profiles and predictive values of some biochemical and haematological quantities in COVID-19 inpatients[J]. Biochem Med (Zagreb),2022, 32(1):010706. doi: 10.11613/BM.2022.010706.
|
[4] |
YANG Y, HU X, XIONG L, et al. Clinical characteristics of hospitalized mild/moderate COVID-19 patients with a prolonged negative conversion time of SARS-CoV-2 nucleic acid detection[J]. BMC Infect Dis, 2021, 21(1):141. doi: 10.1186/s12879-021-05851-z.
|
[5] |
FUKUI S, INUI A, SAITA M, et al. Comparison of the clinical parameters of patients with COVID-19 and influenza using blood test data:a retrospective cross-sectional survey[J]. J Int Med Res, 2022, 50(2):3000605221083751. doi: 10.1177/03000605221083751.
|
[6] |
于洪志, 邵红霞, 邢志珩, 等. 天津地区新型冠状病毒肺炎患者临床特征分析[J]. 天津医药, 2020, 48(7):577-582.
|
|
YU H Z, SHAO H X, XING Z H, et al. Analysis of clinical characteristics of patients with COVID-19 in Tianjin[J]. Tianjin Med J, 2020, 48(7):577-582. doi: 10.11958/20201093.
|
[7] |
GLOCKER M O, OPUNI K F M, THIESEN H J. From free binding energy calculations of SARS-CoV-2-receptor interactions to cellular immune responses[J]. Medicina (Kaunas), 2022, 58(2):226. doi: 10.3390/medicina58020226.
|
[8] |
SINGHAL T. The emergence of Omicron:Challenging times are here again![J]. Indian J Pediatr, 2022, 89(5):490-496. doi: 10.1007/s12098-022-04077-4.
|
[9] |
KIM M K, LEE B, CHOI Y Y, et al. Clinical characteristics of 40 patients infected with the SARS-CoV-2 omicron variant in Korea[J]. J Korean Med Sci, 2022, 37(3):e31. doi: 10.3346/jkms.2022.37.e31.
|
[10] |
SHUAI H, CHAN J F, HU B, et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron[J]. Nature, 2022, 603(7902):693-699. doi: 10.1038/s41586-022-04442-5.
|
[11] |
MENG B, ABDULLAHI A, FERREIRA I A T M, et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity[J]. Nature, 2022, 603(7902):706-714. doi: 10.1038/s41586-022-04474-x.
|
[12] |
WOLTER N, JASSAT W, WALAZA S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa:a data linkage study[J]. Lancet, 2022, 399(10323):437-446. doi: 10.1016/S0140-6736(22)00017-4.
|
[13] |
FEIKIN D R, HIGDON M M, ABU-RADDAD L J, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease:results of a systematic review and meta-regression[J]. Lancet, 2022, 399(10328):924-944. doi: 10.1016/S0140-6736(22)00152-0.
|
[14] |
MODES M E, DIRECTO M P, MELGAR M, et al. Clinical characteristics and outcomes among adults hospitalized with laboratory-confirmed SARS-CoV-2 infection during periods of B.1.617.2(Delta)and B.1.1.529(Omicron)variant predominance - one hospital,California,July 15-September 23,2021,and December 21,2021-January 27,2022[J]. MMWR Morb Mortal Wkly Rep, 2022, 71(6):217-223. doi: 10.15585/mmwr.mm7106e2.
|
[15] |
FANTINI J, YAHI N, COLSON P, et al. The puzzling mutational landscape of the SARS-2-variant Omicron[J]. J Med Virol, 2022, 94(5):2019-2025. doi: 10.1002/jmv.27577.
|